OpenLB
Open Library of Bioscience
Advanced Search
The British journal of dermatology
08, 2022;187 (2): 167-177.

Inflammatory skin diseases and wounds.

Joachim Dissemond, Marco Romanelli
Author Information
  1. Joachim Dissemond: Department of Dermatology, Venerology and Allergology, University of Essen, Essen, Germany. ORCID
  2. Marco Romanelli: Department of Dermatology, University of Pisa, Pisa, Toscana, Italy.
PMID: 35514247 DOI: 10.1111/bjd.21619

Abstract

Inflammatory wounds of the skin can be caused by many different diseases. Of particular importance here are the very heterogeneous groups of vasculitides and vasculopathies. These are usually interdisciplinary relevant diseases that require extensive diagnostics in specialized centres. Clinically, these inflammatory wounds present as very painful ulcers that develop from necrosis and are surrounded by erythematous livid borders. The healing process is often difficult and protracted. Moreover, it considerably impairs the quality of life of the affected patients. In addition to clinical evaluation, histopathological examination of biopsies taken as early as possible is particularly important in diagnosis. Numerous differential diagnoses must be ruled out. Therapeutically, in addition to the often necessary systemic therapies, which include immunosuppressants (immunomodulating drugs and/or rheologics), appropriate topical wound treatment, usually in combination with compression therapy, should always be considered. Whenever possible, the causative factors should be diagnosed early and avoided or treated.

References

  1. Schneider C, Stratman S, Kirsner RS. Lower extremity ulcers. Med Clin North Am 2021; 105:663-79.
  2. Körber A, Klode J, Al-Benna S et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges 2011; 9:116-21.
  3. Dissemond J, Strohal R, Mastronicola D et al. Therapeutic Index for Local Infections score validity: a retrospective European analysis. J Wound Care 2020; 29:726-34.
  4. Watts RA, Lane S, Scott DGI. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005; 19:191-207.
  5. Papi M, Papi C. Vasculitic ulcers. Int J Low Extrem Wounds 2016; 15:6-16.
  6. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1-11.
  7. Sunderkötter CH, Zelger B, Chen KR et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheumatol 2018; 70:171-84.
  8. Marzano AV, Vezzoli P, Berti E. Skin involvement in cutaneous and systemic vasculitis. Autoimmun Rev 2013: 12:467-76. https://doi.org/10.1016/j.autrev.2012.08.005.
  9. Shavit E, Alavi A, Sibbald RG. Vasculitis - what do we have to know? A review of literature. Int J Low Extrem Wounds 2018; 17:218-26.
  10. Jockenhöfer F, Gollnick H, Herberger K et al. Aetiology, comorbidities and cofactors of chronic leg ulcers: retrospective evaluation of 1000 patients from 10 specialised dermatological wound care centers in Germany. Int Wound J 2014; 13:821-8.
  11. Körber A, Schadendorf D, Dissemond J. [Causes of leg ulcers. Analysis of the data from a dermatologic wound care center]. Hautarzt 2009; 60:483-8.
  12. Shanmugam VK, Angra D, Rahimi H, McNish S. Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord 2017; 5:280-92.
  13. Mekkes JR, Loots MA, van der Wal AC, Bos JD. Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol 2004; 50:104-7.
  14. Julanon N, Chularojanamontri L, Sitthinamsuwan P, Sukpanichnant S. Multiple facial ulcers as a presentation of localized granulomatosis with polyangiitis associated with IgG4-related disease. Clin Exp Dermatol 2021; 46:610-13.
  15. Oz RS, Onajin O, Harel L et al. Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis. Pediatr Rheumatol Online J 2021; 19:81.
  16. Dissemond J, Bültemann A, Gerber V et al. Diagnosis and treatment of chronic wounds: current standards of Germany’s Initiative for Chronic Wounds e. V. J Wound Care 2017; 26:727-32.
  17. Ratzinger G, Zelger BG, Carlson JA et al. Vasculitic wheel - an algorithmic approach to cutaneous vasculitides. J Dtsch Dermatol Ges 2015; 13:1092-117.
  18. Gonzalez CD, Florell SR, Bowen AR et al. Histopathologic vasculitis from the periulcer edge: a retrospective cohort study. J Am Acad Dermatol 2019; 81:1353-7.
  19. Isoherranen K, O’Brien JJ, Barker J et al. Atypical wounds. Best clinical practice and challenges. J Wound Care 2019; 28 (Suppl. 6):1-92.
  20. Suppiah R, Mukhtyar C, Flossmann O et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology 2011; 50:899-905.
  21. Li B, Ren Q, Ling J et al. Clinical relevance of neutrophil-to-lymphocyte ratio and mean platelet volume in pediatric Henoch-Schonlein purpura: a meta-analysis. Bioengineered 2021; 12:286-95.
  22. Dissemond J, Erfurt-Berge C, Goerge T et al. Systemic therapies for leg ulcers. J Dtsch Dermatol Ges 2018; 16:873-90.
  23. Mustapha N, Barra L, Carette S et al. Efficacy of leflunomide in the treatment of vasculitis. Clin Exp Rheumatol 2021; 39 (Suppl. 129):114-18.
  24. Tieu J, Smith R, Basu N et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford) 2020; 59:24-32. https://doi.org/10.1093/rheumatology/kez640.
  25. Conway R, O’Neill L, Gallagher P et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum 2018; 48:523-8.
  26. Ferrara G, Giani T, Caparello MC et al. Anakinra for treatment-resistant Kawasaki disease: evidence from a literature review. Paediatr Drugs 2020; 22:645-52.
  27. Stone JH, Tuckwell K, Dimonaco S et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377:317-28.
  28. Cacione DG, Macedo CR, do Carmo Novaes F, Baptista-Silva JC. Pharmacological treatment for Buerger’s disease. Cochrane Database Syst Rev 2020; 5:CD011033. https://doi.org/10.1002/14651858.CD011033.pub4.
  29. Janowska A, Dini V, Oranges T et al. Atypical ulcers: diagnosis and management. Clin Interv Aging 2019; 14:2137-43.
  30. Alavi A, Hafner J, Dutz JP et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol 2013; 69:1033-42.
  31. Maverakis E, Marzano AV, Le ST et al. Pyoderma gangrenosum. Nat Rev Dis Primers 2020; 6:81.
  32. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med 2018; 379:399-400.
  33. Kodumudi V, Jeha GM, Mydlo N, Kaye AD. Management of cutaneous calciphylaxis. Adv Ther 2020; 37:4797-807.
  34. El Hasbani G, Taher AT, Sciascia S, Uthman I. Antiphospholipid syndrome: the need for new international classification criteria. Expert Rev Clin Immunol 2021; 17:385-94.
  35. Nsaful J, Adjei YO, Dedey F et al. Warfarin-induced skin necrosis: a rare condition. Ghana Med J 2020; 54:269-73.
  36. Pejkic S, Savic N, Paripovic M et al. Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review. Vascular 2014; 22:71-6. doi:https://doi.org/10.1177/1708538113478414.
  37. Iba T, Warkentin TE, Connors JM, Levy JH. Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Med 2021; 112:701-12. https://doi.org/10.23736/S0026-4806.21.07469-3.
  38. Berentsen S, Malecka A, Randen U, Tjønnfjord GE. Cold agglutinin disease: where do we stand, and where are we going? Clin Adv Hematol Oncol 2020; 18:35-44.
  39. Basile U, Napodano C, Marino M et al. Cryoglobulins: putative effectors of adaptive immune response. Clin Exp Rheumatol 2021; 39 (Suppl.) 129:171-9.
  40. Paul S, Rabito CA, Vedak P et al. The role of bone scintigraphy in the diagnosis of calciphylaxis. JAMA Dermatol 2017; 153:101-3.
  41. Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021; 14:707-19. doi:https://doi.org/10.1080/17474086.2021.1956898.
  42. Cáliz Cáliz R, Díaz del Campo Fontecha P, Galindo Izquierdo M et al. Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. Reumatol Clín (Engl Ed) 2020; 16 (2 Pt 1):71-86. [Article in English, Spanish] doi:https://doi.org/10.1016/j.reuma.2018.11.003.
  43. Grada A, Falanga V. Cryofibrinogenemia-induced cutaneous ulcers: a review and diagnostic criteria. Am J Clin Dermatol 2017; 18:97-104.
  44. Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag 2019; 15:209-20.
  45. Maverakis E, Ma C, Shinkai K et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol 2018; 154:461-6.
  46. Jockenhöfer F, Wollina U, Salva KA et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019; 180:615-20.
  47. Haag C, Hansen T, Hajar T et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum. J Invest Dermatol 2021; 141:59-63.
  48. Peng T, Zhuo L, Wang Y et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology 2018; 23:669-75.
  49. Janowska A, Oranges T, Fissi A et al. PG-TIME: a practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 2020; 33:e13412.
  50. Ormerod AD, Thomas KS, Craig FE et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015; 350:2958.
  51. Patel F, Fitzmauric S, Duong C et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol 2015; 95:525-31.
  52. Dini V, Romanelli M, Bertone MS et al. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds 2007; 6:108-13.
  53. Ben Abdallah HB, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J 2019; 16:511-21.
  54. Herberger K, Dissemond J, Brüggestrat S et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges 2019; 17:32-41.
  55. López González J, Lázaro Sáez M, Moreno Moraleda I, Hernández Martínez Á. Pyoderma gangrenosum solved by ustekinumab therapy. Gastroenterol Hepatol 2021; 44:299-300.
  56. O’Connor C, Gallagher C, Hollywood A et al. Anakinra for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol 2021; 46:1558-60. https://doi.org/10.1111/ced.14809.
  57. Kolios AG, Maul JT, Meier B et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 2015; 173:1216-23.
  58. Kochar B, Herfarth N, Mamie C et al. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol 2019; 17:991-3.
  59. Dissemond J, Assenheimer B, Engels P et al. M.O.I.S.T. - a concept for the topical treatment of chronic wounds. J Dtsch Dermatol Ges 2017; 15:443-5.
  60. Romanelli M, Dini V, Polignano R et al. Ibuprofen slow-release foam dressing reduces wound pain in painful exuding wounds: preliminary findings from an international real-life study. J Dermatolog Treat 2009; 20:19-26.
  61. Janowska A, Papa G, Romanelli M et al. 5% lidocaine hydrochloride cream for wound pain relief: a multicentre observational study. J Invest Surg 2020; 24:1-4.
  62. Dissemond J, Augustin M, Eming S et al. Modern wound care - practical aspects of non-interventional topical treatment of patients with chronic wounds. J Dtsch Dermatol Ges 2014; 12:541-54.
  63. Kramer A, Dissemond J, Kim S et al. Consensus on wound antisepsis: Update 2018. Skin Pharmacol Physiol 2018; 31:28-58.
  64. Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science 2017; 356:1026-30.
  65. Zakiyanov O, Chocová Z, Hrušková Z et al. Matrix metalloproteinases and their tissue inhibitors: an evaluation of novel biomarkers in ANCA-associated vasculitis. Folia Biol 2019; 65:227-36.
  66. Dissemond J, Augustin M, Dietlein M et al. Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. J Wound Care 2020; 29:102-18.
  67. Schneider LA, Körber A, Grabbe S, Dissemond J. Influence of pH on wound-healing: a new perspective for wound-therapy? Arch Dermatol Res 2007; 298:413-20.
  68. Raffetto JD, Ligi D, Maniscalco R et al. Why venous leg ulcers have difficulty healing: overview on pathophysiology, clinical consequences, and treatment. J Clin Med 2020; 10:E29.
  69. Rabe E, Földi E, Gerlach H et al. [Medical compression therapy of the extremities with medical compression stockings (MCS), phlebological compression bandages (PCB), and medical adaptive compression systems (MAC)]. Hautarzt 2021; 72:137-52.
  70. Janowska A, Romanelli M, Oranges T et al. Prognostic indicators of wound healing in atypical wounds: a case series. Int J Low Extrem Wound 2020; [Online ahead of print]. https://doi.org/10.1177/1534734620970292.
  71. Isobe M, Amano K, Arimura Y et al. JCS 2017 Guideline on management of vasculitis syndrome - digest version. Circ J 2020; 84:299-359.

MeSH Term

Administration, Topical
Dermatitis
Humans
Quality of Life
Skin
Wound Healing
Journal Article Review
Article has an altmetric score of 14

Word Cloud

Created with Highcharts 10.0.0woundsdiseasesInflammatoryskinusuallyoftenadditionearlypossiblecancausedmanydifferentparticularimportanceheterogeneousgroupsvasculitidesvasculopathiesinterdisciplinaryrelevantrequireextensivediagnosticsspecializedcentresClinicallyinflammatorypresentpainfululcersdevelopnecrosissurroundederythematouslividbordershealingprocessdifficultprotractedMoreoverconsiderablyimpairsqualitylifeaffectedpatientsclinicalevaluationhistopathologicalexaminationbiopsiestakenparticularlyimportantdiagnosisNumerousdifferentialdiagnosesmustruledTherapeuticallynecessarysystemictherapiesincludeimmunosuppressantsimmunomodulatingdrugsand/orrheologicsappropriatetopicalwoundtreatmentcombinationcompressiontherapyalwaysconsideredWhenevercausativefactorsdiagnosedavoidedtreated

Similar Articles

Cited By